Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin
The antibacterial activity and selection of resistant bacteria, along with mechanisms of fluoroquinolone resistance, were investigated by integrating the static [MIC or mutant-prevention concentration (MPC)] and in vitro dynamic model approaches using Escherichia coli isolates from diseased dogs. Using the dynamic models, selected E. coli strains and enrofloxacin and marbofloxacin at a range of simulated area under concentration–time curve over a 24 h interval (AUC24 h)/MIC ratios were investigated. Our results indicated increasing losses in susceptibility of E. coli upon continuous exposure to enrofloxacin and marbofloxacin in vitro. This effect was transferable to other fluoroquinolones, as well as to structurally unrelated drugs. Our results also confirmed an AUC24 h/MIC (AUC24 h/MPC)-dependent antibacterial activity and selection of resistant E. coli mutants, in which maximum losses in fluoroquinolone susceptibility occurred at simulated AUC24 h/MIC ratios of 40–60. AUC24 h/MPC ratios of 39 (enrofloxacin) and 32 (marbofloxacin) were considered protective against the selection of resistant mutants of E. coli. Integrating our MIC and MPC data with published pharmacokinetic information in dogs revealed a better effect of the conventional dosing regimen of marbofloxacin than that of enrofloxacin in restricting the selection of resistant mutants of E. coli. Target mutations, especially at codon 83 (serine to leucine) of gyrA, and overexpression of efflux pumps contributed to resistance development in both clinically resistant and in vitro-selected mutants of E. coli. We also report here a previously undescribed mutation at codon 116 of parC in two laboratory-derived resistant mutants of E. coli. Additional studies would determine the exact role of this mutation in fluoroquinolone susceptibility, as well as establish the importance of our findings in the clinical setting.
BallK. R.,
RubinJ. E.,
Chirino-TrejoM.,
DowlingP. M.2008; Antimicrobial resistance and prevalence of canine uropathogens at the Western College of Veterinary Medicine Veterinary Teaching Hospital, 2002–2007. Can Vet J 49:985–990[PubMed]
BoothD. M.2001; Treatment of bacterial infections. In Small Animal Veterinary Pharmacology and Therapeutics pp. 175–221 Edited by
BoothD. M.
Philadelphia, PA: W. B. Saunders;
BootheD. M.,
BoeckhA.,
SimpsonR. B.,
DuboseK.2006; Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. J Vet Intern Med 20:1297–1306 [View Article][PubMed]
CLSI2002Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals, 2nd edn. Approved Standard M31–A2 Wayne, PA: Clinical and Laboratory Standards Institute;
FirsovA. A.,
LubenkoI. Y.,
VostrovS. N.,
KononenkoO. V.,
ZinnerS. H.,
PortnoyY. A.2000; Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother 46:725–732 [View Article][PubMed]
FirsovA. A.,
ZinnerS. H.,
LubenkoI. Y.,
PortnoyY. A.,
VostrovS. N.2002; Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of IE over other integral parameters. Chemotherapy 48:275–279[CrossRef]
FirsovA. A.,
VostrovS. N.,
LubenkoI. Y.,
ArzamastsevA. P.,
PortnoyY. A.,
ZinnerS. H.2004; ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 54:178–186 [View Article][PubMed]
FrazierD. L.,
ThompsonL. L.,
TrettienA.,
EvansE. I.2000; Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs. J Vet Pharmacol Ther 23:293–302 [View Article][PubMed]
GebruE.,
LeeJ. S.,
ChangZ. Q.,
HwangM. H.,
ChengH.,
ParkS. C.2009; Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration. Antimicrob Agents Chemother 53:3024–3029 [View Article][PubMed]
GrobbelM.,
Lübke-BeckerA.,
WielerL. H.,
FroymanR.,
FriederichsS.,
FiliosS.2007; Comparative quantification of the in vitro activity of veterinary fluoroquinolones. Vet Microbiol 124:73–81 [View Article][PubMed]
HeinenE.2002; Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. J Vet Pharmacol Ther 25:1–5 [View Article][PubMed]
InceD.,
HooperD. C.2001; Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus
. Antimicrob Agents Chemother 45:2755–2764 [View Article][PubMed]
IsenbergH. D.1995; Identification methods: aerobic bacteriology. In Clinical Microbiology Procedures Handbook pp. 1.19.1–1.19.58 Washington, DC: American Society for Microbiology;
JohnsonJ. R.,
KuskowskiM. A.,
OwensK.,
ClabotsC.,
SingerR. S.2009; Virulence genotypes and phylogenetic background of fluoroquinolone-resistant and susceptible Escherichia coli urine isolates from dogs with urinary tract infection. Vet Microbiol 136:108–114 [View Article][PubMed]
LitsterA.,
MossS.,
HonneryM.,
ReesB.,
EdinglohM.,
TrottD.2007; Clinical efficacy and palatability of pradofloxacin 2.5 % oral suspension for the treatment of bacterial lower urinary tract infections in cats. J Vet Intern Med 21:990–995 [View Article][PubMed]
MartinezM.,
McDermottP.,
WalkerR.2006; Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet J 172:10–28 [View Article][PubMed]
Minh VienL. T.,
BakerS.,
Phuong ThaoL. T.,
Phuong TuL. T.,
Thu ThuyC.,
Thu NgaT. T.,
Minh HoangN. V.,
CampbellJ. I.,
Minh YenL. et al.2009; High prevalence of plasmid-mediated quinolone resistance determinants in commensal members of the Enterobacteriaceae in Ho Chi Minh City, Vietnam. J Med Microbiol 58:1585–1592 [View Article][PubMed]
MuellerR. S.,
StephanB.2007; Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial. Vet Dermatol 18:144–151 [View Article][PubMed]
MuellerM.,
de la PeñaA.,
DerendorfH.2004; Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 48:369–377 [View Article][PubMed]
NgE. Y.,
TrucksisM.,
HooperD. C.1996; Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus
. Antimicrob Agents Chemother 40:1881–1888[PubMed]
OlofssonS. K.,
MarcussonL. L.,
Komp LindgrenP.,
HughesD.,
CarsO.2006; Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57:1116–1121 [View Article][PubMed]
OramM.,
FisherL. M.1991; 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother 35:387–389[PubMed][CrossRef]
PasqualiF.,
ManfredaG.2007; Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella typhimurium and Pseudomonas aeruginosa
. Vet Microbiol 119:304–310 [View Article][PubMed]
PetersonM. L.,
HovdeL. B.,
WrightD. H.,
BrownG. H.,
HoangA. D.,
RotschaferJ. C.2002; Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 46:203–210 [View Article][PubMed]
PlatellJ. L.,
CobboldR. N.,
JohnsonJ. R.,
TrottD. J.2010; Clonal group distribution of fluoroquinolone-resistant Escherichia coli among humans and companion animals in Australia. J Antimicrob Chemother 65:1936–1938 [View Article][PubMed]
RobertsJ. A.,
KrugerP.,
PatersonD. L.,
LipmanJ.2008; Antibiotic resistance – what’s dosing got to do with it?. Crit Care Med 36:2433–2440 [View Article][PubMed]
RuizJ.2003; Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51:1109–1117 [View Article][PubMed]
VilaJ.,
RuizJ.,
GoñiP.,
De AntaM. T.1996; Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli
. Antimicrob Agents Chemother 40:491–493[PubMed]
VostrovS. N.,
KononenkoO. V.,
LubenkoI. Y.,
ZinnerS. H.,
FirsovA. A.2000; Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob Agents Chemother 44:879–884 [View Article][PubMed]
ZinnerS. H.,
LubenkoI. Y.,
GilbertD.,
SimmonsK.,
ZhaoX.,
DrlicaK.,
FirsovA. A.2003; Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 52:616–622 [View Article][PubMed]
Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin